Nonalcoholic fatty liver disease: A potential consequence of tumor necrosis factor-inhibitor therapy

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 10, 2015, Pages 1154-1160

  Feagins, Linda A ^a,b   Flores, Avegail ^b   Arriens, Cristina ^b   Park, Christina ^a   Crook, Terri ^a,c   Reimold, Andreas ^a,b   Brown, Geri ^a,b  

^a VA North Texas Health Care System   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

inflammatory diseases; nonalcoholic steatohepatitis; PNPLA3; tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ALANINE AMINOTRANSFERASE; ETANERCEPT; INFLIXIMAB; METHOTREXATE; AMINOTRANSFERASE; BIOLOGICAL FACTOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE CONTROL; DRUG EXPOSURE; FEMALE; GENE MUTATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; INFLAMMATORY DISEASE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BIOPSY; BLOOD; NON-ALCOHOLIC FATTY LIVER DISEASE; TREATMENT OUTCOME;

BIOLOGICAL FACTORS; BIOPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; TRANSAMINASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTORS;

EID: 84942040926     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000421     Document Type: Article

References (30)

1. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387-1395.
2. Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143:722-728.
3. Dixon JB, Bhathal PS, OBrien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121:91-100.
4. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006; 45:600-606.
5. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int 2009; 29:113-119.
6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55:2005-2023.
7. Karvounaris SA, Sidiropoulos PI, Papadakis JA, Spanakis EK, Bertsias GK, Kritikos HD, et al. Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. Ann Rheum Dis 2007; 66:28-33.
8. Da Cunha VR, Brenol CV, Brenol JC, Fuchs SC, Arlindo EM, Melo IM, et al. Metabolic syndrome prevalence is increased in rheumatoid arthritis patients and is associated with disease activity. Scand J Rheumatol 2012; 41:186-191.
9. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157:68-73.
10. Nijsten T, Wakkee M. Complexity of the association between psoriasis and comorbidities. J Invest Dermatol 2009; 129:1601-1603.
11. Puig L, Strohal R, Husni ME, Tsai TF, Noppakun N, Szumski A, et al. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. J Dermatolog Treat 2015; 26:7-15.
12. Nagahori M, Hyun SB, Totsuka T, Okamoto R, Kuwahara E, Takebayashi T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol 2010; 45:1008-1013.
13. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343:1467-1476.
14. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
15. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
16. Ozorio G, McGarity B, Bak H, Jordan AS, Lau H, Marshall C. Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis. Med J Aust 2007; 187:524-526.
17. Nakayama S. Autoimmune hepatitis triggered by anti-TNF-alpha therapy. Case Rep Med 2013; 2013:561748.
18. Cravo M, Silva R, Serrano M. Autoimmune hepatitis induced by infliximab in a patient with Crohns disease with no relapse after switching to adalimumab. BioDrugs 2010; 24 (Suppl 1):25-27.
19. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, et al. Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11:558-564. e553.
20. McGowan CE, Jones P, Long MD, Barritt AS 4th. Changing shape of disease: nonalcoholic fatty liver disease in Crohns disease - a case series and review of the literature. Inflamm Bowel Dis 2012; 18:49-54.
21. Di Minno MN, Iervolino S, Peluso R, Russolillo A, Lupoli R, Scarpa R, et al. Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-alpha blockers. J Rheumatol 2012; 39:1042-1046.
22. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53:1883-1894.
23. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio LA, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40:1461-1465.
24. Ruiz AG, Casafont F, Crespo J, Cayón A, Mayorga M, Estebanez A, et al. Lipopolysaccharide-binding protein plasma levels and liver TNFalpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17:1374-1380.
25. Bahcecioglu IH, Yalniz M, Ataseven H, Ilhan N, Ozercan IH, Seckin D, Sahin K. Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology 2005; 52:1549-1553.
26. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37:343-350.
27. Satapathy SK, Garg S, Chauhan R, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99:1946-1952.
28. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol 2004; 99: 2365-2368.
29. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52:1836-1846.
30. Chalasani N, Wilson L, Kleiner DE, Cummings OW, Brunt EM, Unalp A. NASH Clinical Research Network. Relationship of steatosis grade and zonal location to histological features of steatohepatitis in adult patients with non-alcoholic fatty liver disease. J Hepatol 2008; 48:829-834.